Overview

Trabectedin Combined With Durvalumab in Patients With Advanced Pretreated Soft-tissue Sarcomas and Ovarian Carcinomas.

Status:
Active, not recruiting

Trial end date:
2021-12-01

Target enrollment:

Participant gender:

Summary

A phase Ib trial study of trabectedin when prescribed in combination with durvalumab in locally advanced/unresectable soft-tissue sarcoma and ovarian carcinomas.

Phase:

Phase 1

Details

Lead Sponsor:

Institut Bergonié

Collaborators:

AstraZeneca
PharmaMar

Treatments:

Antibodies, Monoclonal
Durvalumab
Trabectedin